We only have this paper's title and publication details.
Read it at the sourceRuxolitinib inhibits MPN cell migration and expression of MMP-2 and MMP-9 via JAK2 signal pathway.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: